(AOF) – Geneuro, a biotech specialist in treatments for neurodegenerative and autoimmune diseases, and the severe neuropsychiatric consequences of Covid-19 (post-Covid or long Covid), announced today the publication in the scientific journal of Translational Psychiatry reference of a study showing that more than 80% of patients hospitalized during the first wave of the Covid-19 pandemic in a psychiatric department in the Paris region had been exposed to SARS-Cov-2 – i.e. 1.6 times more than in the control group.
This study shows that infection by SARS-CoV-2, even unnoticed or asymptomatic, in psychotic patients, can have an influence on the activation of endogenous human retrovirus W (HERV-W), in a context of innate immune inflammation.
It highlights “the urgency as well as the possibility of developing new therapeutic methods and approaches for the treatment of psychotic patients” for whom the HERV-W ENV protein is activated, for example by viruses in genetically susceptible individuals.
GeNeuro has initiated a program with temelimab, (an antibody directed against HERV-W ENV) for patients with persistent neuropsychiatric symptoms following long Covid. The company launched a phase 2 trial at the end of 2022, called GNC-501, which evaluates the clinical effectiveness of a six-month treatment with temelimab on the improvement of cognitive impairment and/or fatigue in patients with long and positive for the W-ENV protein in the blood.
© 2023 Agence Option Finance (AOF) – All rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
